B-Cell Lymphomas, Version 6.2023 Featured Updates to the NCCN Guidelines

被引：57

作者：

Zelenetz, Andrew D. ^{[1
]}

Gordon, Leo, I ^{[2
]}

Abramson, Jeremy S. ^{[3
]}

Advani, Ranjana H. ^{[4
]}

Andreadis, Babis ^{[5
]}

Bartlett, Nancy L. ^{[6
,7
]}

Budde, L. Elizabeth ^{[8
]}

Caimi, Paolo F. ^{[9
,10
]}

Chang, Julie E. ^{[11
]}

Christian, Beth ^{[12
,13
]}

DeVos, Sven ^{[14
]}

Dholaria, Bhagirathbhai ^{[15
]}

Fayad, Luis E. ^{[16
]}

Habermann, Thomas M. ^{[17
]}

Hamid, Muhammad Saad ^{[18
]}

Hernandez-Ilizaliturri, Francisco ^{[19
]}

Hu, Boyu ^{[20
]}

Kaminski, Mark S. ^{[21
]}

Karimi, Yasmin ^{[21
]}

Kelsey, Christopher R. ^{[22
]}

King, Rebecca ^{[17
]}

Krivacic, Susan

LaCasce, Ann S. ^{[23
]}

Lim, Megan ^{[1
]}

Messmer, Marcus ^{[24
]}

Narkhede, Mayur ^{[25
]}

Rabinovitch, Rachel ^{[26
]}

Ramakrishnan, Praveen ^{[27
]}

Reid, Erin ^{[28
]}

Roberts, Kenneth B. ^{[29
]}

Saeed, Hayder ^{[30
]}

Smith, Stephen D. ^{[31
]}

Svoboda, Jakub ^{[32
]}

Swinnen, Lode J. ^{[33
]}

Tuscano, Joseph ^{[34
]}

Vose, Julie M. ^{[35
]}

Dwyer, Mary A. ^{[36
]}

Sundar, Hema ^{[36
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[4] Stanford Canc Inst, Stanford, CA USA

[5] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[6] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[7] Washington Univ, Sch Med, St Louis, MO USA

[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[9] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[10] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[11] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[12] Ohio State Univ, Comprehens Canc Ctr, James Canc Hosp, Columbus, OH USA

[13] Solove Res Inst, Columbus, OH USA

[14] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Mayo Clin, Comprehens Canc Ctr, Rochester, MI USA

[18] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN USA

[19] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[20] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[21] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[22] Duke Canc Inst, Durham, NC USA

[23] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[24] Fox Chase Canc Ctr, Philadelphia, PA USA

[25] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA

[26] Univ Colorado, Canc Ctr, Aurora, CO USA

[27] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[28] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA

[29] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[30] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[31] Fred Hutchinson Canc Ctr, Seattle, WA USA

[32] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[33] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[34] Univ Calif Davis, Comprehens Canc Ctr, Davis, CA USA

[35] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[36] Natl Comprehens Canc Network, Washington, DC USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2023年 / 21卷 / 11期

关键词：

TERM-FOLLOW-UP; NON-HODGKINS-LYMPHOMA; HIGH-DOSE THERAPY; SINGLE-ARM; OPEN-LABEL; LISOCABTAGENE MARALEUCEL; INDUCTION CHEMOTHERAPY; MARROW-TRANSPLANTATION; AUTOLOGOUS TRANSPLANT; FOLLICULAR LYMPHOMA;

D O I：

10.6004/jnccn.2023.0057

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

jugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in themanagement ofmantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19CAR T-cell therapies are noweffective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), andMCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, andMCL.

引用

页码：1118 / 1131

页数：14

共 86 条

[1] Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study [J].

Abramson, Jeremy S. ;

Solomon, Scott R. ;

Arnason, Jon ;

Johnston, Patrick B. ;

Glass, Bertram ;

Bachanova, Veronika ;

Ibrahimi, Sami ;

Mielke, Stephan ;

Mutsaers, Pim ;

Hernandez-Ilizaliturri, Francisco ;

Izutsu, Koji ;

Morschhauser, Franck ;

Lunning, Matthew ;

Crotta, Alessandro ;

Montheard, Sandrine ;

Previtali, Alessandro ;

Ogasawara, Ken ;

Kamdar, Manali .

BLOOD, 2023, 141 (14) :1675-1684

[2] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[3] The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms [J].

Alaggio, Rita ;

Amador, Catalina ;

Anagnostopoulos, Ioannis ;

Attygalle, Ayoma D. ;

Araujo, Iguaracyra Barreto de Oliveira ;

Berti, Emilio ;

Bhagat, Govind ;

Borges, Anita Maria ;

Boyer, Daniel ;

Calaminici, Mariarita ;

Chadburn, Amy ;

Chan, John K. C. ;

Cheuk, Wah ;

Chng, Wee-Joo ;

Choi, John K. ;

Chuang, Shih-Sung ;

Coupland, Sarah E. ;

Czader, Magdalena ;

Dave, Sandeep S. ;

de Jong, Daphne ;

Du, Ming-Qing ;

Elenitoba-Johnson, Kojo S. ;

Ferry, Judith ;

Geyer, Julia ;

Gratzinger, Dita ;

Guitart, Joan ;

Gujral, Sumeet ;

Harris, Marian ;

Harrison, Christine J. ;

Hartmann, Sylvia ;

Hochhaus, Andreas ;

Jansen, Patty M. ;

Karube, Kennosuke ;

Kempf, Werner ;

Khoury, Joseph ;

Kimura, Hiroshi ;

Klapper, Wolfram ;

Kovach, Alexandra E. ;

Kumar, Shaji ;

Lazar, Alexander J. ;

Lazzi, Stefano ;

Leoncini, Lorenzo ;

Leung, Nelson ;

Leventaki, Vasiliki ;

Li, Xiao-Qiu ;

Lim, Megan S. ;

Liu, Wei-Ping ;

Louissaint, Abner, Jr. ;

Marcogliese, Andrea ;

Medeiros, L. Jeffrey .

LEUKEMIA, 2022, 36 (07) :1720-1748

[4] Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib [J].

Awan, Farrukh T. ;

Schuh, Anna ;

Brown, Jennifer R. ;

Furman, Richard R. ;

Pagel, John M. ;

Hillmen, Peter ;

Stephens, Deborah M. ;

Woyach, Jennifer ;

Bibikova, Elena ;

Charuworn, Prista ;

Frigault, Melanie M. ;

Hamdy, Ahmed ;

Izumi, Raquel ;

Linghu, Bolan ;

Patel, Priti ;

Wang, Min Hui ;

Byrd, John C. .

BLOOD ADVANCES, 2019, 3 (09) :1553-1562

[5] Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure [J].

Ayers, Emily C. ;

Li, Shaoying ;

Medeiros, L. Jeffrey ;

Bond, David A. ;

Maddocks, Kami J. ;

Torka, Pallawi ;

Hicks, Angel Mier ;

Curry, Madeira ;

Wagner-Johnston, Nina D. ;

Karmali, Reem ;

Behdad, Amir ;

Fakhri, Bita ;

Kahl, Brad S. ;

Churnetski, Michael C. ;

Cohen, Jonathon B. ;

Reddy, Nishitha M. ;

Modi, Dipenkumar ;

Ramchandren, Radhakrishnan ;

Howlett, Christina ;

Leslie, Lori A. ;

Cytryn, Samuel ;

Faramand, Rawan ;

Chavez, Julio C. ;

Olszewski, Adam J. ;

Liu, Yang ;

Barta, Stefan K. ;

Mukhija, Dhruvika ;

Hill, Brian T. ;

Ma, Helen ;

Amengual, Jennifer E. ;

Nathan, Sunita ;

Assouline, Sarit E. ;

Orellana-Nola, Victor M. ;

Portell, Craig A. ;

Chandar, Ashwin ;

David, Kevin A. ;

Giri, Anshu ;

Hess, Brian T. ;

Landsburg, Daniel J. .

CANCER, 2020, 126 (02) :293-303

[6]

Bartlett NL, 2022, Blood, V140

[7] Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Brown, J. R. ;

Eichhorst, B. ;

Hillmen, P. ;

Jurczak, W. ;

Kazmierczak, M. ;

Lamanna, N. ;

O'Brien, S. M. ;

Tam, C. S. ;

Qiu, L. ;

Zhou, K. ;

Simkovic, M. ;

Mayer, J. ;

Gillespie-Twardy, A. ;

Ferrajoli, A. ;

Ganly, P. S. ;

Weinkove, R. ;

Grosicki, S. ;

Mital, A. ;

Robak, T. ;

Osterborg, A. ;

Yimer, H. A. ;

Salmi, T. ;

Wang, M. -D. -Y. ;

Fu, L. ;

Li, J. ;

Wu, K. ;

Cohen, A. ;

Shadman, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (04) :319-332

[8] Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study [J].

Budde, Lihua E. ;

Sehn, Laurie H. ;

Matasar, Matthew ;

Schuster, Stephen J. ;

Assouline, Sarit ;

Giri, Pratyush ;

Kuruvilla, John ;

Canales, Miguel ;

Dietrich, Sascha ;

Fay, Keith ;

Ku, Matthew ;

Nastoupil, Loretta ;

Cheah, Chan Yoon ;

Wei, Michael C. ;

Yin, Shen ;

Li, Chi-Chung ;

Huang, Huang ;

Kwan, Antonia ;

Penuel, Elicia ;

Bartlett, Nancy L. .

LANCET ONCOLOGY, 2022, 23 (08) :1055-1065

[9] Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial [J].

Byrd, John C. ;

Hillmen, Peter ;

Ghia, Paolo ;

Kater, Arnon P. ;

Chanan-Khan, Asher ;

Furman, Richard R. ;

O'Brien, Susan ;

Yenerel, Mustafa Nuri ;

Illes, Arpad ;

Kay, Neil ;

Garcia-Marco, Jose A. ;

Mato, Anthony ;

Pinilla-Ibarz, Javier ;

Seymour, John F. ;

Lepretre, Stephane ;

Stilgenbauer, Stephan ;

Robak, Tadeusz ;

Rothbaum, Wayne ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Patel, Priti ;

Higgins, Kara ;

Sohoni, Sophia ;

Jurczak, Wojciech .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (31) :3441-+

[10]

Byrne Michael, 2019, Biol Blood Marrow Transplant, V25, pe344, DOI [10.1016/j.bbmt.2019.06.036, 10.1016/j.bbmt.2019.06.036]

← 1 2 3 4 5 6 7 8 9 →